Annexon initiates Phase 3 ARCHER II GA trial; Phase 2 data show vision protection

Annexon, Inc.

Dosing started in global pivotal Phase 3 ARCHER II trial of ANX007 for geographic atrophy (GA).
Topline data expected in second half of 2026; trial to enroll ~630 patients.
Phase 2 ARCHER: ANX007 reduced ≥15-letter BCVA loss to 5.6% vs sham 21.3% (p=0.0021).
Structural protection: up to 60% photoreceptor preservation in central fovea (p=0.0319).
FDA/EMA aligned on BCVA as primary endpoint; EU PRIME and US Fast Track designations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.